Jiří Ferda1, Eva Ferdová2, Jan Baxa2, Jindřich Fínek3, Ondřej Topolčan4. 1. Department of Imaging Methods, Charles University Hospital Pilsen, Pilsen, Czech Republic ferda@fnplzen.cz. 2. Department of Imaging Methods, Charles University Hospital Pilsen, Pilsen, Czech Republic. 3. Department of Oncology and Radiotherapy, Charles University Hospital Pilsen, Pilsen, Czech Republic. 4. Immunoanalytic Laboratory, Charles University Hospital Pilsen, Pilsen, Czech Republic.
Abstract
AIM: To evaluate our own experience with 18F- fluoromethylcholine-(FCH)-positron-emission tomography combined with magnetic resonance imaging (PET/MRI) in restaging of patients with prostatic carcinoma and elevated serum prostate-specific antigen (PSA) level. PATIENTS AND METHODS: The analysis was performed on a sample of 100 male patients who underwent 18F-FCH-PET/MRI, with a mean age of 63.2 years (range=47-78 years). The imaging was performed using an integrated PET/MRI hybrid system after intravenous application of 18F-FCH at a dose of 1.25 MBq/kg. The number and sites of pathological accumulation of FCH related to local recurrence, nodal spread and skeletal metastases were compared to corresponding MRI findings; furthermore, the relation of PSA level and presence of FCH accumulation in tumorous tissue was assessed; finally we correlated the findings of different sites of metastatic involvement. RESULTS: In patients with a PSA level up to 2 ng/ml, accumulation in tumorous tissue of local recurrence or metastases was found in 83.33% in cases of biochemical relapse, and in patients with PSA level above 5 ng/ml in 100% of cases. In general, we found any finding explained rise of PSA level in 94% of patients. CONCLUSION: 18F-FCH-PET/MRI using an integrated system with 1,25 MBq/kg dosing of FCH is a valuable tool in evaluation of restaging in patients with prostatic carcinoma, with high detection rate even in those with a low serum PSA level. Copyright
AIM: To evaluate our own experience with 18F- fluoromethylcholine-(FCH)-positron-emission tomography combined with magnetic resonance imaging (PET/MRI) in restaging of patients with prostatic carcinoma and elevated serum prostate-specific antigen (PSA) level. PATIENTS AND METHODS: The analysis was performed on a sample of 100 male patients who underwent 18F-FCH-PET/MRI, with a mean age of 63.2 years (range=47-78 years). The imaging was performed using an integrated PET/MRI hybrid system after intravenous application of 18F-FCH at a dose of 1.25 MBq/kg. The number and sites of pathological accumulation of FCH related to local recurrence, nodal spread and skeletal metastases were compared to corresponding MRI findings; furthermore, the relation of PSA level and presence of FCH accumulation in tumorous tissue was assessed; finally we correlated the findings of different sites of metastatic involvement. RESULTS: In patients with a PSA level up to 2 ng/ml, accumulation in tumorous tissue of local recurrence or metastases was found in 83.33% in cases of biochemical relapse, and in patients with PSA level above 5 ng/ml in 100% of cases. In general, we found any finding explained rise of PSA level in 94% of patients. CONCLUSION:18F-FCH-PET/MRI using an integrated system with 1,25 MBq/kg dosing of FCH is a valuable tool in evaluation of restaging in patients with prostatic carcinoma, with high detection rate even in those with a low serum PSA level. Copyright
Authors: Laura Evangelista; Fabio Zattoni; Gianluca Cassarino; Paolo Artioli; Diego Cecchin; Fabrizio Dal Moro; Pietro Zucchetta Journal: Eur J Nucl Med Mol Imaging Date: 2020-09-08 Impact factor: 9.236
Authors: Laura Evangelista; Gianluca Cassarino; Alberto Lauro; Alessandro Morlacco; Matteo Sepulcri; Alex Ahn Li Nguyen; Francesco Ietto; Diego Cecchin; Carmelo Lacognata; Pietro Zucchetta Journal: Abdom Radiol (NY) Date: 2021-05-28